BCL2 is a pro-survival protein that protects myeloma cells from drug-induced death [35] and is often over-expressed in cancer cells exhibiting the CIN phenotype, even though it should be down regulated following drug-dependent mitotic arrest [15, 36, 37]. This evidence concerns the gene BCL2 and plasma cell myeloma.